Tolerability was acceptable in both treatment arms ; the most frequent grade 3/4 treatment-related adverse events ( arm B vs. arm A ) were fatigue ( 6.6 vs. 16.1 % ) , diarrhoea ( 3.3 vs. 11.3 % ) , anorexia ( 3.3 vs. 11.3 % ) , and neuropathy ( 1.6 vs. 8.1 % ) .